Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The goal of this randomized clinical trial is to assess if adjunctive bosentan therapy, in comparison to placebo, can reduce the rate of epicardial vasospasm at follow-up spasm provocation CFT (fuCFT) in patients with previously proven epicardial vasospasm on acetylcholine reactivity testing (at index CFT) and ongoing angina(-like) complaints.
Participants will
* Use either endothelin receptor antagonist or placebo for 10 weeks
* Undergo follow-up acetylcholine spasm provocation test after 10 weeks
* Answer online questionnaires on angina and quality of life
Phase:
PHASE2
Details
Lead Sponsor:
Radboud University Medical Center
Collaborators:
Catharina Ziekenhuis Eindhoven Maasstad Hospital UMC Utrecht